1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

What’s Next? Five Things To Look Out For In December

Key Trial Kicks Off For Viatris; US Treanda Generics Set To Debut

 
• By Dean Rudge

In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.

What's Next Image
Much is to come at the end of 2022 • Source: Citeline

Viatris may have removed recently another significant legal hurdle to launching its Breyna US generic version of AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler, but it is not out of the woods yet.

The ANDA sponsor is set to face trial against the UK-based originator over a fifth asserted Symbicort patent, US patent...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products